Clinical Trials Logo

AIDS-related Lymphoma clinical trials

View clinical trials related to AIDS-related Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05510908 Recruiting - HIV Infections Clinical Trials

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

Start date: July 25, 2023
Phase:
Study type: Observational

This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people.

NCT ID: NCT05231135 Recruiting - Clinical trials for AIDS Related Lymphoma

A Registry Study on HIV-related Lymphoma

Start date: August 25, 2021
Phase:
Study type: Observational [Patient Registry]

Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.

NCT ID: NCT03220022 Recruiting - Clinical trials for Ann Arbor Stage III Diffuse Large B-Cell Lymphoma

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Start date: March 16, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride may work better in treating patients with HIV-positive diffuse large B-cell lymphomas.